Similar articles

• Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.

  Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I; SHIFT Investigators. Swedberg K, et al. J Am Coll Cardiol. 2012 May 29;59(22):1938-45. doi: 10.1016/j.jacc.2012.01.020. J Am Coll Cardiol. 2012. PMID: 22617188 Clinical Trial.
• SHIFTING the burden of heart failure.

  [No authors listed] [No authors listed] Cardiovasc J Afr. 2010 Sep-Oct;21(5):302. Cardiovasc J Afr. 2010. PMID: 20972527 Free PMC article. No abstract available.
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Swedberg K, et al. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Lancet. 2010. PMID: 20801500 Clinical Trial.
• I(f) current and heart rate control.

  César LA. César LA. Arq Bras Cardiol. 2007 Apr;88(4):e99-e102. doi: 10.1590/s0066-782x2007000400031. Arq Bras Cardiol. 2007. PMID: 17546262 Review. English, Portuguese. No abstract available.
• Update on ivabradine for heart failure.

  Borer JS, Tavazzi L. Borer JS, et al. Trends Cardiovasc Med. 2016 Jul;26(5):444-9. doi: 10.1016/j.tcm.2016.01.004. Epub 2016 Jan 28. Trends Cardiovasc Med. 2016. PMID: 26934996 Review.